Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.35 |
| ▸ | CDK1 | P06493 | 4/20 | 0.35 |
| ▸ | CDK4 | P11802 | 4/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.35 |
| ▸ | CCND1 | P24385 | 4/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204351 | 0.91 | GRM4 (0.37) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL1241448 | 0.90 | CCNE1 (0.41) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL1241714 | 0.89 | CDK2 (0.35) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL2657485 | 0.88 | PPARG (0.34) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL2657483 | 0.88 | PPARG (0.34) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL1241401 | 0.87 | CCNE1 (0.38) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL1240419 | 0.87 | CDK2 (0.37) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL1241701 | 0.86 | CCNE1 (0.42) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL1240730 | 0.85 | CCNE1 (0.51) | CDK2CCNE1CCNE2ADORA2AADORA1 | |
| SCHEMBL1240727 | 0.85 | CCNE1 (0.51) | CDK2CCNE1CCNE2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CDK2 268/4885CCNE1 2561/4885CCNE2 1371/4885 |
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CDK2 268/4885CCNE1 2561/4885CCNE2 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.